Navigation Links
Algeta Appoints Andrew Kay as President and Chief Executive Officer
Date:12/11/2008

utics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.

Algeta's lead product candidate, Alpharadin, has commenced phase III clinical trials in hormone-refractory prostate cancer based on positive phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers.

Algeta is also developing other technologies for delivering alpha emitters. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

About Alpharadin

Alpharadin is a unique targeted treatment for skeletal metastases in cancer patients and is based on radium-223. The clinical development of Alpharadin is most advanced in hormone refractory prostate cancer (HRPC) that has spread to bone, where it is now in an international phase III trial. In a phase II trial completed in 2007 involving 64 men with metastatic HRPC, Alpharadin was shown to increase life expectancy by over 40%, and was found to be exceptionally well tolerated.

Clinical data from this and other trials suggest Alpharadin may also have a role in the treatment of other high-incidence metastatic cancers.

Algeta began its pivotal phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study in mid-2008 and it is now ongoing in several countries in Europe. Approximately 750 patients are expected to be enrolled at more than 125 medical centers in Europe, Asia, South America and Canada. The international trial is evaluating Alpharadin in metastatic HRPC with overall survival as the primary endpoint.

Alpharadin in also in a phase I trial in the USA under Investigational New
'/>"/>

SOURCE Algeta ASA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
(Date:12/19/2014)... 19, 2014  Roche (SIX: RO, ROG; OTCQX: RHHBY) ... (Bina), a privately held company based in ... provides a big data platform for centralized management ... Bina,s proprietary on-market Genomic Management Solution, Bina-GMS 1 ... perform fast and scalable analyses to maximize the ...
(Date:12/19/2014)... Dec. 19, 2014 Research and Markets ... of the "Technology Innovations in Smart Fabrics ... http://photos.prnewswire.com/prnh/20130307/600769 ... Fabrics" offers a detailed assessment on technological advancements ... Findings: 1. The Smart Fabrics ...
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel drug ... Eye Institute (NEI) at the National Institutes of Health ... to develop a drug-eluting intraocular lens (IOL) for cataract ... vision loss in people over age 40 and the ... Mandell, LayerBio’s Founder and CEO, "There is a critical ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... to Present at Rodman & Renshaw Annual Global Investment Conference -- BEIJING, Sept. 7 /PRNewswire-Asia-FirstCall/ -- ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... IRVINE, Calif., Sept. 7 ChromaDex Corporation (OTC Bulletin ... company which provides novel and innovative ingredients to the ... a clinical study at The University of Mississippi for ... based on the grant of an exclusive worldwide license ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting at the ... at 10:55 a.m. ET / 7:55 a.m. PT ... Healthcare Conference on Tuesday, September 14, 2010 at 11:30 a.m. ... Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will ...
Cached Biology Technology:Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 2Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 3Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 4Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 5Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 6Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 7ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene 2ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene 3
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... pan out. Neither did two other potential anti-aging agents. ... is now a front- runner in ongoing animal experiments ... inflammation, cancer and other destructive processes, can boost the ... meeting of the American Aging Association, University of Michigan ...
... discovery of how some abnormal cells can avoid a ... and repairing the damage, is giving investigators at St. ... cancer cells use to survive and thrive. , The ... have cheated death once by disabling the main suicide ...
... (DPI) fisheries scientists are investigating ways to boost the ... by anglers. , Some guidelines designed to improve fish ... trevally, mulloway, sand whiting, yellowfin bream and dusky flathead. ... and funded by NSW DPI and the Recreational Fishing ...
Cached Biology News:Agent slows aging in mice 2Cells re-energize to come back from the brink of death 2Releasing fish for the future 2
... and ES1301 mutS are mismatch repair minus ... strains prevents repair of the newly synthesized ... efficiencies and making them helpful in such ... II Mutagenesis Systems. Both ES1301 and BMH ...
Request Info...
... ExcelGel DNA Analysis Kit, 1. ... polymorphisms and high resolution DNA typing. ... set-up and clean-up. *Precast, plastic-backed gels ... handling convenience and detection sensitivity. ...
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Biology Products: